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Abstract Adhesion molecules can initiate intracellular signal-
ing. Engagement of CD44 either by its natural ligand hyalur-
onan or a speci¢c antibody on a cell line induced tyrosine phos-
phorylation and activation of focal adhesion kinase (FAK),
which then associated with phosphatidylinositol 3-kinase
(PI3K) and activated mitogen-activated protein kinase at its
downstream. However, the introduction of dominant negative
Rho into the cells inhibited the CD44-stimulated FAK phosphor-
ylation. Cells expressing CD44 were signi¢cantly resistant to
etoposide-induced apoptosis. This anti-apoptotic e¡ect was can-
celled by the inhibition of either Rho, FAK or PI3K. These
results may indicate a signaling pathway from CD44 to medi-
ate the resistance against drug-induced apoptosis in cancer
cells. , 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
CD44 is a broadly distributed type I transmembrane glyco-
protein receptor for the glycosaminoglycan hyaluronan (HA),
a major component of extracellular matrix (ECM) [1^4].
CD44 has been recognized for its structural roles in linking
ECM with the cellular actin cytoskeleton to regulate cell
shape and cell migration [2^4]. At its N-terminus, CD44 has
the HA-binding domain whose primary structure has signi¢-
cant similarity with other HA-binding proteins such as carti-
lage link protein [2^4]. The 72 amino acid cytoplasmic domain
of CD44 has been shown to associate with actin micro¢la-
ments mediated by ezrin, radixin, and moesin family members
of proteins [4,5]. In the extracellular membrane proximal re-
gion, there may be insertion of various amino acid sequences
caused by alternative splicing among at least 10 variable
exons. Thus, a single CD44 gene would potentially produce
over 1000 isoforms. A form of CD44 without any variable
exons is referred to as the standard form (CD44s; also called
CD44H) and is most widely distributed. CD44 is overex-
pressed in many cancers including colorectal carcinomas [6],
at least partly because it is one of the target genes of the Wnt
pathway [6] that is up-regulated in the carcinomas due mainly
to the loss of APC gene function [7]. Furthermore, there are
numerous reports concerning several CD44 isoforms, espe-
cially those containing the sequence of exon v6, that plays
an important role in the processes of invasion and metastasis
in neoplastic cells [2^4,8^10]. In addition, one of the major
CD44 isoforms, which contains the sequence from exons v8^
v10, is called the epithelial form (CD44E; also referred to as
CD44R1 in the literature), and it is expressed in normal epi-
thelial cells as well as in many cancer cells [2,9].
Focal adhesion kinase (FAK) is a cytoplasmic protein ty-
rosine kinase (PTK) that has been considered to play a central
role in cellular responses to ECM glycoproteins like ¢bronec-
tin, which signal through integrin receptors [11,12]. However,
FAK is also implicated in the responses to a number of other
cellular stimuli that generate signals through either G-protein
linked receptors (e.g. bombesin and thrombin), transmem-
brane growth factor receptors, or other, as yet unknown
mechanisms [12]. For some of these stimuli like bombesin
and thrombin, the events leading to increased FAK tyrosine
phosphorylation have been shown to be dependent upon the
activity of the small GTP binding protein p21 Rho [12^14].
Rho functions as a molecular switch for many intracellular
processes by converting its inactive GDP binding form to its
active GTP binding form [15]. FAK is associated with a num-
ber of signaling proteins that enable this PTK to couple
to a variety of intracellular signaling pathways, extracellular
signal-regulated kinase mitogen-activated protein kinase
(MAPK) cascade and phosphatidylinositol 3-kinase (PI3K)
pathway being but two of them [12,16,17].
In addition to its connection to cytoskeleton, the cytoplas-
mic domain of CD44 has been shown to associate with Src
family PTKs whose activities are up-regulated by ligation of
CD44 in hematopoietic cells [18^20]. However, the biological
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signi¢cance of this phosphorylation has remained unclear.
Through our experiments using a non-hematopoietic human
CD44-negative cancer cell line, we found that cells expressing
CD44E bind more avidly to HA than those expressing CD44s
(Nakamura, S. and Harigaya, K., unpublished result). Using
these cell lines, we attempted to elucidate the molecular mech-
anisms of intracellular signaling from CD44.
2. Materials and methods
2.1. Reagents
An anti-CD44 monoclonal antibody (mAb), Hermes 3, was puri¢ed
from conditioned medium of hybridoma HB-9480 that had been pur-
chased from American Type Culture Collection (ATCC, Rockvill,
MD, USA). An anti-CD44 mAb that can block its ligand binding
(BRIC 235) [21] was purchased from Biogenesis (New Field, UK).
An anti-hemagglutinin (12CA5) and anti-Myc (9E10) monoclonal
antibodies were also prepared from hybridomas. Anti-phosphotyro-
sine (pTyr) antibody (PY20), anti-FAK antibody (sc-558), anti-Tiam1
antibody (sc-872) and anti-PI3K p85 (sc-423) were purchased from
Santa Cruz (Santa Cruz, CA, USA). Anti-phosphoMAPK was from
New England Biolabs (Beverly, MA, USA). HA preparations of var-
ious molecular weights were generously provided by Seikagaku Co.
(Tokyo, Japan). Protein contents of these preparations were under the
detection limit as judged by UV absorption at 280 nm. Bovine serum
albumin (BSA) (Fraction V), LY294002 and PD98059 were purchased
from Sigma (St. Louis, MO, USA).
2.2. Cell culture
A human lung small cell cancer cell line, NCI-H82 (ATCC HTB-
175), was cultured in Iscove’s modi¢ed Eagle’s medium (IMEM) (Gib-
co BRL, Grand Island, NY, USA) supplemented with 10% fetal bo-
vine serum (FBS). Various transfectants of NCI-H82 were grown in
the same medium containing appropriate selection agents to stabilize
the transgenes.
2.3. DNA construction and transfection to cells
The NCI-H82 cells were stably transfected with full-length human
CD44E cDNA [22] cloned into pCIneo mammalian expression vector
(Promega, Madison, WI, USA) by lipofection procedure with
DMRIE-C reagent (Gibco BRL). As a control, pCIneo was trans-
fected to the cells. Stable transfectants were selected in the growth
medium containing 1.0 mg/ml of G418 (Gibco BRL). The transfected
cells were cloned by limiting dilution. The resultant clones were
termed 82E and 82pCI, respectively.
The cDNA of mutant FAK is known to have two mutations
(Tyr397Phe, the binding site for Src and PI3K p85, and Lys454Arg,
the ATP-binding site in the kinase domain) and three hemagglutinin
epitopes at its N-terminus [23]. The cDNA of RhoA dominant neg-
ative mutant (Thr19Asn) with a Myc-epitope tag was as described
[24]. These cDNAs were cloned into pMx retrovirus vector [25]. Re-
combinant retroviruses were produced by co-transfecting various pMx
vectors and amphotropic helper virus DNA [26] into 293T cells. 82E
cells and their derivatives were infected with the recombinant retro-
viruses by culturing in conditioned media in the presence of polybrene
(Sigma). For expression of the mutant FAK and the dominant neg-
ative mutant of RhoA, retroviral introduction was performed three
times to increase the fraction of the cells expressing the proteins.
Empty vector control was also introduced three times. The transfec-
tants were designated as 82E-mutFAK, 82E-dnRhoA and 82E-pMX,
respectively.
2.4. Cell adhesion assay
Cells (1U105 cells/well) were incubated for 30 min at 37‡C in a 96-
well plate (Sumitomo Bakelite, Tokyo, Japan) which had been coated
with HA (32 kDa; 10 mg/ml) together with BSA (100 mg/ml) as an
anchor for the immobilization. Wells coated with BSA alone were
used as controls. Following the incubation, cells that had not been
adhered were washed away with phosphate-bu¡ered saline. Propor-
tion of the adhered cells to the total cells incubated was estimated
with the MTT assay as described [27,28].
For assessing the dependency of the adhesion on CD44, cells were
preincubated with concentrations of an anti-CD44 mAb (BRIC 235)
or an isotype-matched control IgG (IgG2b) (Immunotech, Marseille,
France) for 30 min at 4‡C before the adhesion assay.
2.5. Cell stimulation
Cells were starved in IMEM containing 0.5% FBS for 24 h before
stimulation. The cells (5U105 cells/ml) were then cultured in IMEM
(serum-free) containing 10 Wg/ml of HA or 10 Wg/ml of anti-CD44
mAb (Hermes 3) at 37‡C for the indicated periods.
2.6. Immunoprecipitation and Western blotting
Cells were lysed by suspension in an ice-cold bu¡er (20 mM
HEPES^NaOH (pH 7.9), 0.5% Nonidet P-40, 15% glycerol, 300
mM NaCl, 1 mM EDTA, 10 mM NaF, 1 mM sodium orthovanadate,
1 Wg/ml leupeptin, 1 Wg/ml pepstatin, 1 Wg/ml aprotinin, 1 mM dithio-
threitol and 0.5 mM phenylmethylsulfonyl £uoride) for 30 min [28,29].
The supernatants were saved as total cell lysates following centrifu-
gation. The lysates from each cell were immunoprecipitated by incu-
bation with the anti-FAK or the anti-Tiam1 antibody for 2 h on ice.
Immune complexes were collected on protein G-Sepharose (Pharma-
cia, Uppsala, Sweden), washed ¢ve times in the lysis bu¡er, and pro-
teins were eluted with sample bu¡er (62.5mM Tris^HCl (pH 6.8), 2%
SDS, 10% glycerol, 5% 2-mercaptoethanol and 0.02% bromophenol
blue) for SDS^polyacrylamide gel electrophoresis (PAGE). The pro-
teins were resolved on SDS^PAGE and transferred to polyvinylidene
di£uoride membranes (Bio-Rad Laboratories, Hercules, CA, USA).
Primary antibodies reacted to the antigens on the membranes were
detected using the appropriate horseradish peroxidase-conjugated sec-
ondary antibodies (Pharmacia or Santa Cruz) and the Super Signal
chemiluminescence detection system (Pierce, Rockford, IL, USA) as
suggested by the manufacturer.
2.7. Kinase assay
PTK assay for FAK was performed with a non-radioactive enzyme-
linked immunosorbent assay kit (Universal Tyrosine Kinase Assay
Kit, Takara Shuzou Co., Shiga, Japan) according to the manufactur-
er’s instructions. Cell lysates equivalent to 250 Wg of protein were
immunoprecipitated with the anti-FAK antibody. After washing, the
immunoprecipitates were incubated with ATP in poly(Glu-Tyr)-
coated 96-well plates. After washing, pTyr was detected with peroxi-
dase-conjugated anti-pTyr (PY20) antibody and TMBZ chromogenic
substrates.
2.8. DNA fragmentation and cell viability assays
Cells (4U105 cells/ml) were preincubated for 1 h with 10 WM
LY294002 (Sigma) or 50 WM PD98059 (Sigma) in IMEM with 0.5%
FBS on 96-well plates. Then, etoposide (10 Wg/ml) was included in the
culture for 24 h. Cell viability was determined by the MTT assay
[27,28]. For DNA fragmentation assay, cells (1.5U106) were lysed
in a lysis bu¡er (10 mM Tris^HCl (pH 7.4), 10 mM EDTA, 0.5%
Triton X-100), and then treated sequentially with RNase (20 Wg/ml)
and proteinase K (20 Wg/ml). Lysates were electrophoresed on 2%
agarose gel with visualization by 0.1% ethidium bromide.
3. Results
To investigate the functions of CD44, an expression vector
for CD44E, or its empty counterpart, was transfected into a
CD44-negative cancer cell line to establish stable transform-
ants. We isolated several clones expressing CD44E (82E) (Fig.
1A). 82pCI clones, which had been transfected with the empty
vector, expressed no detectable CD44 protein (Fig. 1A). As
shown in Fig. 1B, 82E clones exhibited robust adhesion to the
culture wells coated with HA, while 82pCI clones showed
little adhesion to the wells. Adhesion to BSA-coated wells
was essentially invariant among the 82E and 82pCI clones
(Fig. 1B). The HA-mediated adhesion of the 82E clone was
blocked by pre-incubating the cells with a well-characterized
blocking antibody for CD44 (BRIC 235) [21] in a dose-depen-
dent manner (Fig. 1C). This antibody also inhibited the adhe-
sion of other 82E clones to a similar extent with the clone at
the concentration of 10 Wg/ml (data not shown). An isotype-
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matched antibody did not inhibit the adhesion of the clones at
this concentration (Fig. 1C; data not shown). The adhesion
was also signi¢cantly inhibited by adding soluble HA in the
medium (250 Wg/ml; data not shown). These results indicate
that CD44 expressed in the cell line can reconstitute HA-
mediated cell adhesion, one of the major functions of CD44
molecule [2^4]. Thus, 82E cells would be a valid model system
to assess physiological functions of CD44.
Upon stimulation by HA, we observed tyrosine phosphor-
ylation of several cellular proteins in 82E clones but not in
82pCI clones (Fig. 2A). The phosphorylated proteins included
those with approximate molecular weights of 130, 125, 100, 80
and 65 kDa (Fig. 2A). For further studies, we employed one
from each group (clone1 from 82pCI and clone13 from 82E)
as representatives.
HA exists as a high molecular weight polymer (usually over
1000 kDa) in its native state [30^32]. However, under condi-
tions such as tissue injury, low molecular weight HA accumu-
lates [31^37]. As shown in Fig. 2B, although HA of all mo-
lecular weights (including that with high molecular weight)
induced tyrosine phosphorylation, HA with a low molecular
weight was the strongest inducer of the response. For subse-
quent studies, we utilized the low molecular weight HA (32
kDa) that evoked the strongest reaction.
CD44 has no recognizable tyrosine kinase domain in its
intracellular domain [4]. To identify the kinase(s) involved
in the tyrosine phosphorylation of 82E, the lysates of the cells
stimulated with the low molecular weight HA were immuno-
precipitated with an anti-FAK antibody and immunoblotted
with an anti-pTyr mAb. As shown in Fig. 2C, FAK with a
molecular weight of 125 kDa was tyrosine-phosphorylated in
82E cells but not in 82pCI cells at their non-stimulated state.
Ligand stimulation strongly increased the phosphorylation of
FAK in 82E, but not in 82pCI. Furthermore, ligation of
CD44 with a mAb directed against the extracellular domain
of CD44 (Hermes 3) also increased the tyrosine phosphoryla-
tion of FAK (Fig. 2C). To examine whether this phosphory-
lation re£ects the activation of FAK, the kinase activity of the
anti-FAK immunoprecipitates was assayed with poly(Glu-
Tyr) as a substrate [38]. Fig. 2D shows that the CD44 ligation
Fig. 1. Establishment of human cancer cell lines with or without CD44 expression. A: Expression of CD44 in NCI-H82 cells. Cell lysates from
82pCI and 82E cells were immunoblotted with the anti-CD44 mAb (Hermes 3). B: HA-mediated adhesion of 82E cells. Vertical axis represents
the percentage of adhered cells among the cells seeded. Error bars indicate standard deviations (n=6). C: E¡ect of an anti-CD44 blocking
mAb on the HA-mediated adhesion of the 82E cl13 cells. Vertical axis represents percentage of adhered cells. Error bars indicate standard devi-
ations (n=3). Open circles represent groups treated with the anti-CD44 mAb and an open square indicates a group treated with isotype-
matched control IgG2b. The results given by other clones were essentially invariable (data not shown).
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by either HA or the antibody up-regulated the FAK-associ-
ated PTK activity by about 1.5- to 1.7-fold in 82E as com-
pared with the non-stimulated cells or 82pCI control cells.
After the ligation of CD44 by the antibody, tyrosine phos-
phorylation of FAK could be observed as early as 1 min later,
peaking at 5 min and subsequently decreasing (Fig. 2E). The
time-course of tyrosine phosphorylation after the stimulation
with HA was similar to that with the antibody (data not
shown). Tyrosine kinases may initiate downstream signaling
reactions including kinase cascades [39]. A major autophos-
phorylation site of FAK, Tyr-397 [40], has been shown to be
the binding site for the p85 subunit of PI3K [23]. As shown in
Fig. 2. CD44 ligation-induced activation of FAK and its downstream molecules. A: CD44-dependent tyrosine phosphorylation of cellular pro-
teins activated by HA. 82pCI and 82E cells were stimulated with HA (molecular weight= 32 kDa) for 5 min or left untreated. Lysates were im-
munoblotted with the anti-pTyr mAb (PY20). B: Strength of tyrosine phosphorylation induced by HA is dependent on its molecular weight.
HA of various molecular weights was used as stimulant in the same assay as A. C: CD44E ligation-induced tyrosine phosphorylation of FAK.
82pCI or 82E cells were stimulated with HA (molecular weight = 32 kDa) or the anti-CD44 mAb for 5 min. Lysates were immunoprecipitated
with anti-FAK antibody followed by immunoblotting with anti-pTyr. The ¢lter membrane was re-blotted with anti-FAK to demonstrate equal
protein loading. D: CD44 ligation-induced activation of FAK. The anti-FAK immunoprecipitates were subjected to a PTK assay. Results are
shown as meanUS.D. (n=3). E: Kinetics of tyrosine phosphorylation of FAK and its association with PI3K p85 after ligation of CD44. 82E
was stimulated with anti-CD44 mAb for various periods. Lysates were immunoprecipitated with anti-FAK and blotted sequentially with anti-
pTyr, anti-PI3K p85 and anti-FAK. As a control for co-immunoprecipitation, the lysate from the cells stimulated for 15 min was immunopreci-
pitated with the anti-Tiam1 antibody. F: CD44E ligation-induced activation of MAPK. Lysates analyzed in E were also immunoblotted with
anti-phosphoMAPK antibody, followed by anti-MAPK.
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Fig. 2E, the immunoprecipitates of the anti-FAK antibody
from the antibody-stimulated 82E cells contained PI3K p85.
Fig. 2E also shows that an unrelated antibody (anti-Tiam1
antibody) does not co-precipitate PI3K p85, indicating the
association of PI3K complex with the tyrosine-phosphorylat-
ed FAK. This association began 1 min after the ligation and
thereafter was sustained for at least 60 min. Another well-
documented downstream target molecule of FAK is MAPK
[16,28]. As shown in Fig. 2F, both Erk-1 and Erk-2 were
activated by the CD44 ligation. This activation also began
1 min after the ligation, remained at a high level for 30 min,
and then decreased by 60 min (Fig. 2F).
In order to investigate whether these biochemical reactions
resulted from the activation of FAK, we introduced a mutant
FAK into 82E cells by a retrovirus-mediated gene transfer
system (Fig. 3A). In these cells (82E-mutFAK), CD44 liga-
tion-induced tyrosine phosphorylation of FAK was almost
completely inhibited (Fig. 3B). As shown in Fig. 3B,C, the
augmentation of FAK^PI3K association and MAPK activa-
tion by CD44 ligation were strongly inhibited in the cells
expressing the mutant FAK, while these e¡ects were still evi-
dent in mock-infected control cells. These results indicate that
FAK mediates outside^in CD44 signaling to activate PI3K
and MAPK.
Clarifying the functional link between CD44 and FAK is of
major interest. In repeated experiments, however, we could
not detect any physical association of FAK with CD44. There
is evidence that FAK is one of the targets of Rho [12^14].
Furthermore, we obtained results to indicate that CD44 liga-
tion induces activation of Rho (Kumagai, S., Kitagawa, M.,
and Harigaya, K., unpublished result). When 82E cells were
treated with C3 exotoxin, a speci¢c inhibitor of Rho, CD44
ligation-induced FAK activation was inhibited (data not
shown), indicating the involvement of Rho in this process.
Retrovirus-mediated transfection of the dominant negative
form of RhoA into 82E cells (82E-dnRhoA) (Fig. 4A) almost
completely inhibited the tyrosine phosphorylation of FAK in
response to CD44 ligation (Fig. 4B). These results indicate
that Rho mediates the CD44 ligation-induced FAK activation
in this system.
There are some indications that CD44 ligation renders cells
resistant to apoptosis [41,42]. Furthermore, targeted deletions
of exon 7, or exons 6 and 7, of the CD44 gene in mice results
in increased apoptosis of in¢ltrating mononuclear cells in
models of enterocolitis [43]. Consistent with these reports,
82E cells showed a marked resistance against induction of
cell death by the anti-cancer drug etoposide (VP16) compared
Fig. 3. Expression of mutant FAK inhibited CD44 ligation-induced FAK^PI3K association and MAPK activation. A: Expression of mutant
FAK in 82E cells. Cell lysates from 82E-pMx and 82E-mutFAK cells were immunoblotted with anti-hemagglutinin-tag mAb. B: Expression of
mutant FAK inhibited CD44 ligation-induced tyrosine phosphorylation of FAK and its association with PI3K p85. The cells were stimulated
with anti-CD44 mAb for 5 min. Anti-FAK immunoprecipitates were immunoblotted with anti-pTyr, anti-PI3K p85 and anti-FAK. C: Expres-
sion of mutant FAK inhibited CD44 ligation-induced activation of MAPK. Lysates analyzed in B were immunoblotted with anti-phospho-
MAPK or anti-MAPK.
Fig. 4. Expression of a dominant negative form of Rho inhibited
CD44 ligation-induced tyrosine phosphorylation of FAK. A: Ex-
pression of dominant negative RhoA mutant. Cell lysates of 82E-
pMx and 82E-dnRhoA cells were immunoblotted with anti-Myc-tag
antibody. B: Expression of dominant negative RhoA mutant inhib-
ited CD44 ligation-induced tyrosine phosphorylation of FAK. The
cells were stimulated with anti-CD44 mAb for 5 min. Anti-FAK im-
munoprecipitates were immunoblotted with anti-pTyr and anti-
FAK.
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to 82pCI cells (Fig. 5A). 90% of 82E cells were viable after
treatment with etoposide for 24 h, whereas 82pCI showed no
more than 30% viability (Fig. 5A). Notably, the viability of
both 82E-mutFAK and 82E-dnRhoA cells was 35% or less, a
similar level to that of 82pCI (Fig. 5A). In 82pCI, 82E-
dnRhoA and 82E-mutFAK cells, the etoposide treatment in-
duced DNA fragmentation, an indication of apoptosis (Fig.
5B). These results suggest that the CD44/Rho/FAK pathway
transduces an anti-apoptotic signal(s).
Both of the downstream kinases of FAK in this system,
PI3K and MAPK, were reported to have anti-apoptotic e¡ect
[44]. However, the inhibition of cell viability loss and DNA
fragmentation by etoposide was markedly reversed by treat-
ment with a speci¢c PI3K inhibitor, LY294002, but not with a
speci¢c MEK inhibitor, PD98059 (Fig. 5C,D). Additionally,
LY294002 treatment also reduced the survival of NCI-H82
cells expressing CD44s to the levels of the control 82pCI cells
in etoposide-containing cultures (data not shown). These re-
sults indicate that PI3K, but not MAPK, is essential for the
anti-apoptotic signal downstream of FAK. In this study, the
CD44-dependent anti-apoptotic phenotype was conferred to
the cells without the addition of HA (Fig. 5). This suggests
that the HA present in the serum-containing culture medium
[30,45] and/or produced by the cells themselves would be suf-
¢cient for the weak but still signi¢cant FAK phosphorylation
(Fig. 2C) and the anti-apoptotic e¡ect.
4. Discussion
There have been a number of reports concerning CD44
ligation-induced cellular responses. They include enhancement
of cell motility [46,47], expression of adhesion molecules
Fig. 5. Resistance to apoptosis mediated by CD44/Rho/FAK pathway. A: Resistance to etoposide-induced cell death caused by CD44 expres-
sion and its inhibition by FAK or Rho mutants. 82pCI, 82E, 82E-mutFAK and 82E-DNRhoA cells were treated with etoposide and cell viabil-
ity was determined by MTT assay. Results are shown as meansUS.D. (n=3). B: Resistance to etoposide-induced DNA fragmentation caused
by CD44 expression and its inhibition by FAK or Rho mutants. Cells analyzed in A were also analyzed for DNA fragmentation. C: A speci¢c
inhibitor of PI3K but not an inhibitor of MAPK inhibited CD44-induced resistance to apoptosis. 82E cells were treated with etoposide after
LY294002 or PD98059 pretreatment. Cell viability was measured by MTT assay. Results are shown as meansUS.D. (n=3). D: A speci¢c in-
hibitor of PI3K but not an inhibitor of MAPK inhibited CD44-induced resistance to DNA fragmentation. Cells analyzed in C were also ana-
lyzed for DNA fragmentation.
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[48,49] and a growth factor receptor [49], cytokine and chemo-
kine secretion [31,50^52], and protection from apoptosis [41^
43]. At the biochemical level, CD44 ligation has been shown
to activate Rac1 [53^55] and nuclear factor-UB [36]. It has also
been reported that ligation of CD44 activates Src family
PTKs associated with the cytoplasmic domain of CD44 [18^
20], although none of the cellular responses has been linked to
the activation of PTKs. We have demonstrated a novel func-
tional association between FAK and CD44, which leads to a
CD44-mediated anti-apoptotic e¡ect. In 10 other non-trans-
fected CD44-positive cell lines examined, FAK was heavily
tyrosine-phosphorylated without any stimulation and the
blocking antibodies against CD44 did not reduce the level
of the phosphorylation (data not shown). These results sug-
gest that the activation of FAK by the ligand stimulation of
CD44 may take place under the limited situation of the cells.
It could be cell lineage speci¢c or an alteration concomitant
with neoplastic transformation.
Stimulation of another HA receptor, RHAMM, has also
been demonstrated to activate FAK and MAPK [56,57].
However, the activation of FAK and MAPKs shown in this
report is clearly dependent on CD44, as CD44-negative con-
trol cells did not respond to HA stimulation, and the speci¢c
antibody against CD44 mimicked the natural ligand in its
e¡ect.
Activation of FAK by ligation of an adhesion molecule is
reminiscent of integrin signaling [11,12]. As opposed to integ-
rin signaling [12], however, the CD44-induced FAK activation
is dependent on Rho. Thus, it is possible that integrins are not
involved in this signaling from CD44 to FAK.
In addition to providing structural tethering points for cells,
some adhesion molecules transduce signals that result in a
broad range of cellular processes. We presented a molecular
mechanism for CD44 signaling that directs cell survival
against exposure to a cytotoxic agent. This study indicates
that FAK would be a mediator of outside^in CD44 signaling
under a limited cellular environment.
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